Tinea corporis Infections and Infestations
Conditions
Interventions
The statistician employs a computer-generated randomization technique to allocate the participants randomly into two groups: Group A and Group B. Group A receive MEBO treatment, while Group B receive
Sponsors
José R. Reyes Memorial Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Filipino 2. Either sex 3. Aged 12 to 75 years old 4. Clinically diagnosed tinea corporis and confirmed by by the presence of long, narrow, septated and branching hyphae on microscopic examination of skin scrapings in 10% KOH preparation
Exclusion criteria
Exclusion criteria: 1. Patients with lesions involving more than 20% of total body surface area 2. Those with concomitant active, localized, or systemic infection 3. Those with concurrent dermatoses 4. Individuals in an immunocompromised state 5. Patients who had used topical and systemic steroids, immunomodulating drugs, keratolytic agents, or topical and systemic antifungals within the last 30 days 6. Individuals with known or suspected hypersensitivity to azoles, Coptidis rhizome, Phellodendri chinensis cortex, Scutellariae radix, sesame oil and beeswax
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Clinical response assessed using the Physician’s Global Assessment (PGA) based on induration, erythema, and scaling 2. Mycological cure determined by potassium hydroxide (KOH) examination under direct microscopy, evaluating the presence and quantity of hyphae Measurements will be conducted at baseline, week 4, and week 8. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. •Patient-reported pruritus evaluated using the 5-D Pruritus Scale at baseline, week 4, and week 8 2. Treatment satisfaction score measured by the treatment satisfaction questionnaire for medication (TSQM-9) at the end of the study | — |
Countries
Philippines
Contacts
Public ContactAngeli Carina Lahoz
Outcome results
None listed